Long-term Safety of GnRHa Affirmed in Premenopausal Women Un

In premenopausal women with early breast cancer, use of a gonadotropin-releasing hormone agonist during chemotherapy did not increase the risk of cancer recurrence for up to 12 years, according to the PROMISE-GIM6 trial.

Related Keywords

New York , United States , Italy , Columbia University , Italian , Neil Vasan , N Lynn Henry , University Of Genova , Reuters Health , University Of Michigan Rogel Cancer Center , Journal Of The National Cancer Institute , Columbia University Medical Center , National Cancer Institute , Lucia Del Mastro , Del Mastro , Disease Lead , Breast Oncology , Michigan Rogel Cancer Center , Ann Arbor , Herbert Irving Comprehensive Cancer Center , New York City , Katherine Crew , Breast Cancer , Alignant Breast Neoplasm , Breast Carcinoma , Chemotherapy , Cancer , Alignant Neoplasia , Arcinoma , Alignant Neoplasm , Breast , Mammary Gland , Menopause , Menopausal Syndrome , Adjuvant Chemotherapy , Clinical Research , Clinical Trials , Linical Studies , Cancer Risk , Gnrh Agonists , Gonadotropin Releasing Hormone Agonists , Nrh A , Adverse Effects , Side Effects , Ovarian Insufficiency ,